Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Panzem Nanocrystal Colloidal Dispersion · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Panzem Nanocrystal Colloidal Dispersion (NCD) | DRUG | Panzem NCD 1,000 mg, four times daily for 28 consecutive days |
| Panzem Nanocrystal Colloidal Dispersion | DRUG | Panzem NCD suspension, 100 mg/mL, four times daily continuous dosing |
Inclusion Criteria: 1. Written informed consent and HIPAA authorization for release of protected health information. 2. Have histologically-confirmed: * epithelial ovarian cancer or * primary peritoneal carcinomatosis or * fallopian tube cancer. Enrollment of patients with clear cell hist...
Top 20 of 59 competitors
Panzem Nanocrystal Colloidal Dispersion is an investigational small molecule being studied in oncology. It has been evaluated in Phase 2 clinical trials for recurrent glioblastoma multiforme and ovarian cancer. The drug is not approved and remains in clinical development.
Panzem Nanocrystal Colloidal Dispersion is being developed by CASI Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker CASI. The company is conducting clinical trials of the drug in the United States.
Panzem Nanocrystal Colloidal Dispersion is in Phase 2 clinical development. Two Phase 2 trials have been completed, one in recurrent glioblastoma multiforme and one in ovarian cancer. The drug is investigational and has not been approved by regulatory authorities.
Panzem Nanocrystal Colloidal Dispersion has completed two Phase 2 trials. NCT00306618 studied the drug in 27 patients with recurrent glioblastoma multiforme, and NCT00400348 studied it in 18 female patients with ovarian cancer. Both trials were conducted in the United States.
Panzem Nanocrystal Colloidal Dispersion is a small molecule oncology drug. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being studied for its safety and efficacy in treating recurrent glioblastoma multiforme and ovarian cancer.